General information about company							
Name of The Company	Tatva Chintan Pharma Chem Limited						
BSE Scrip Code	543321						
NSE Symbol	TATVA						
MSE Symbol	NOTLISTED						
Date of Start of Financial Year	01-04-2021						
Date of End of Financial Year	31-03-2022						
Reporting Period	First half yearly						
Date of Start of Reporting Period	01-04-2021						
Date of End of Reporting Period	30-09-2021						
Level of rounding used in financial results	Millions						
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes						

Related party transactions												
		Sr	1	2	3	4	5	6	7	8	9	10
A. Details of related party		Name of the related party	Tatva Chintan USA Inc	Tatva Chintan Europe B.V	Shital C Shah	Priti A Patel	Kajal S Somani	Mahesh Tanna	Apurva Dubey	Chintan N Shah	Ajay M Patel	Shekhar R Somani
		Categories of related parties	Subsidiaries	Subsidiaries	Promoters Group	Promoters Group	Promoters Group	Key management personnel of entity or parent	Key management personnel of entity or parent	Promoters	Promoters	Promoters
		description of relationship	Wholly owned Subsidiary	Wholly owned Subsidiary	Spouse of Director	Spouse of Director	Spouse of Director	Chief Financial Officer	Company Secretary	Managing Director	Whole-time Director	Whole-time Director
		PAN of related party										
		CIN of related party										
		Purchase of goods and										
		Sale of goods and	286849920	170253675								
		services Purchase of	200047720	170233073								
		fixed assets Sale of fixed										
		assets Rendering										
		of services Receiving of										
		services Leases										
		Loans and advances										
		given Loans and										
		advances taken										
		Loans and advances given that are repaid										
		Loans and advances taken that										
		are repaid Deposits										
		placed Deposits										
		taken Transfer of										
		research & development Transfers										
		under lease agreement										
		Equity										
B. Details of related		Impairment in equity investment										
party transactions		Expense for bad or doubtful										
		Guarantees										
		or collateral given Guarantees										
		or collateral taken										
		Interest income Interest paid										
		Dividend income										
		Dividend paid										
		Management contracts										
		including for deputation of										
		employees Settlement										
		of liabilities by entity on behalf of										
		Short term employee			300000	300000	300000	2043777	214639	8251625	8251625	8251625
		benefits Post			30000	30000	30000	2043777	214037	0231023	0231023	0231023
	Remuneration	employment benefits Other long-										
	Remuneration	term benefits										
		Termination benefits										
		Share based payments						4				
C. Outstanding balances	Dacainal-1	Others Secured						14132	1042	9000	1500	260068
	Receivables	Un Secured Secured	110715475	53068449								
	Payables	Un Secured Secured			38430	38800	38800		33900	764755	763255	801384
	Loans and advances	Un Secured		290626								
	given Loans and advances	Secured Un Secured										
1	taken							i				

taken

	Deposits	Secured									
	placed	Un Secured	<u> </u>	<u> </u>			'	<u> </u>	<u> </u>		
	Deposits	Secured					<u></u> '				
1	taken	Un Secured			,		<u>'</u>				
1	Guarantees or	Secured			,		<u>'</u>				
1	collateral	Un Secured					<u> </u>				
'	given Guarantees or	Secured			,		<u>, </u>				
1	collateral	Un Secured			,I		<u> </u>				
	taken Investment in	Secured		<u> </u>	<u> </u>						
	equity	Un Secured	6656000	9523	,I		<u> </u>				
	Provision for	Secured		<u> </u>	<u> </u>						
	doubtful debt	Un Secured			,I		<u> </u>				
Note			Others transaction includes reimbursement of expenses incurred for or on behalf								
			of Company	of Company	of Company	of Company	of Company				